Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/annrheumdis-2020-217416 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Burden of coronary artery calcification in ANCA-associated vasculitis.
RMD Open
January 2025
Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
Background: Cardiovascular disease (CVD) is a leading cause of death in ANCA-associated vasculitis (AAV). Screening and primary cardiovascular prevention may improve outcomes.
Methods: We identified patients in the 2002-2019 Mass General Brigham AAV cohort with thoracic CT scans obtained for other clinical purposes.
History of antineutrophil cytoplasmic autoantibodies : Milestones in rheumatology.
Z Rheumatol
December 2024
Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands.
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are autoimmune inflammatory small-vessel disorders with potentially life-threatening organ manifestations. Recent disease definitions and classification criteria allow distinction between granulomatosis with polyangiitis (GPA), eosinophilic granulomatosis with polyangiitis (EGPA), and non-granulomatous microscopic polyangiitis (MPA). The discovery of ANCA-autoantibodies directed against proteolytic enzymes of neutrophil granules-has enabled earlier diagnosis of AAV and paved the way to stage-adapted treatments.
View Article and Find Full Text PDFComparison of different ANCA detection methods in a predominantly MPO-ANCA-associated vasculitis cohort.
Immunol Med
October 2024
Division of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.
Article Synopsis
- The study evaluated various ANCA detection methods in a group of 147 patients with untreated ANCA-associated vasculitis, focusing primarily on myeloperoxidase (MPO)-ANCA.
- Different testing methods were compared, including immunofluorescence (IIF) and several antigen-specific immunoassays (ELISA, CLEIA, FEIA, LTIA), revealing varying sensitivities and specificities for diagnosing AAV.
- Results indicated that while antigen-specific immunoassays performed well overall, using dual IIF and these immunoassays had limited benefits, and standardizing ANCA measurements across different methods remained challenging.
Study protocol for a randomised, phase II, double-blind, experimental medicine study of obinutuzumab versus rituximab in ANCA-associated vasculitis: ObiVas.
BMJ Open
July 2024
Department of Medicine, University of Cambridge, Cambridge, UK
Introduction: Relapses in ANCA-associated vasculitis (AAV) increase the incidence of end-organ damage and their prevention requires prolonged immunosuppressive therapy. Rituximab, a type I anti-CD20 B cell depleting monoclonal antibody, is the current standard of care for induction of disease remission. Rituximab is not always effective and is associated with a high subsequent relapse risk.
View Article and Find Full Text PDFPredictive Factors of Renal Recovery and Progression to End-Stage Kidney Disease in Patients With Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis With Severe Kidney Disease.
Kidney Int Rep
May 2024
Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA.
Introduction: A significant number of patients with antineutrophil cytoplasmic antibodies (ANCA)- associated vasculitis (AAV) with glomerulonephritis (AAV-GN) still progress to end-stage kidney disease (ESKD, estimated glomerular filtration rate [eGFR] <15 ml/min per 1.73 m) despite advances in remission-induction treatment.
Methods: This is a retrospective cohort study on myeloperoxidase (MPO)-ANCA or proteinase 3 (PR3)-ANCA positive patients with AAV (microscopic polyangiitis, MPA; or granulomatosis with polyangiitis, GPA) and eGFR <15 ml/min per 1.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!